Centre d'oncologie de précision

Equipe principale
Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


136 publications

Sous presse | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2011 | 2008 |
Sous presse
 
Dynamic 3D genome reorganization during senescence: defining cell states through chromatin.
Shaban H.A., Gasser S.M. Cell death and differentiation. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_50916437809C]
 
Genome-wide analysis of the biophysical properties of chromatin and nuclear proteins in living cells with Hi-D.
Valades-Cruz C.A., Barth R., Abdellah M., Shaban H.A. Nature protocols. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EC86BF4494A6]
2024
 
Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma.
de Joode K., Mora A.R., van Schaik RHN, Zippelius A., van der Veldt A., Gerard C.L., Läubli H., Michielin O., von Moos R., Joerger M. et al., 2024/06/01. Journal of immunotherapy, 47 (5) pp. 190-194. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B6930E6F147C]
 
Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy.
Taylor A.M., McKeown J., Dimitriou F., Jacques S.K., Zimmer L., Allayous C., Yeoh H.L., Haydon A., Ressler J.M., Galea C. et al., 2024/03. European journal of cancer, 199 p. 113561. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CB58FC4C5C60]
 
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy.
Jacques S.K., McKeown J., Grover P., Johnson D.B., Zaremba A., Dimitriou F., Weiser R., Farid M., Namikawa K., Sullivan R.J. et al., 2024/03. European journal of cancer, 199 p. 113563. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AD78846E78A2]
Strategies to decrease inequalities in cancer therapeutics, care and prevention: Proceedings on a conference organized by the Pontifical Academy of Sciences and the European Academy of Cancer Sciences, Vatican City, February 23-24, 2023.
Ringborg U., von Braun J., Celis J., Baumann M., Berns A., Eggermont A., Heard E., Heitor M., Chandy M., Chen C.J. et al., 2024/02. Molecular oncology, 18 (2) pp. 245-279. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E812852CFCF3]
 
The features and management of acquired resistance to PD1-based therapy in metastatic melanoma.
Hepner A., Versluis J.M., Wallace R., Allayous C., Brown L.J., Trojaniello C., Gerard C.L., Jansen Y.J., Bhave P., Neyns B. et al., 2024/01. European journal of cancer, 196 p. 113441. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2852520524D8]
2023
Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient.
Anchisi S., Wolfer A., Bisig B., Missiglia E., Tiab A., Kamel E.M., Michielin O., Coukos G., Homicsko K., 2023/12/31. Cancer biology & therapy, 24 (1) p. 2193116. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_365141E36CC9]
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab.
Mallardo D., Woodford R., Menzies A.M., Zimmer L., Williamson A., Ramelyte E., Dimitriou F., Wicky A., Wallace R., Mallardo M. et al., 2023/10/25. Journal of translational medicine, 21 (1) p. 753. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_79C70FD3661F]
Testing a Model of Care for Patients on Immune Checkpoint Inhibitors Based on Electronic Patient-Reported Outcomes: Protocol for a Randomized Phase II Controlled Trial.
da Silva Lopes A.M., Colomer-Lahiguera S., Darnac C., Giacomini S., Bugeia S., Gutknecht G., Spurrier-Bernard G., Cuendet M., Muet F., Aedo-Lopez V. et al., 2023/10/18. JMIR research protocols, 12 pp. e48386. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FB6569F97D27]
Immuno-oncology approaches in uveal melanoma: tebentafusp and beyond.
Gerard C., Shum B., Nathan P., Turajlic S., 2023/09. Immuno-oncology technology, 19 p. 100386. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_D41F65D6A18E]
Modeling tumor size dynamics based on real-world electronic health records and image data in advanced melanoma patients receiving immunotherapy.
Courlet P., Abler D., Guidi M., Girard P., Amato F., Vietti Violi N., Dietz M., Guignard N., Wicky A., Latifyan S. et al., 2023/08. CPT, 12 (8) pp. 1170-1181. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A319336A78BD]
Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors.
da Silva Lopes A.M., Colomer-Lahiguera S., Darnac C., Giacomini S., Bugeia S., Gutknecht G., Spurrier-Bernard G., Aedo-Lopez V., Mederos N., Latifyan S. et al., 2023/07/22. Supportive care in cancer, 31 (8) p. 484. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EC47A57CA4E0]
Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors.
Schmidt J., Chiffelle J., Perez MAS, Magnin M., Bobisse S., Arnaud M., Genolet R., Cesbron J., Barras D., Navarro Rodrigo B. et al., 2023/06/06. Nature communications, 14 (1) p. 3188. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2898FB2D9415]
Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways.
Spain L., Coulton A., Lobon I., Rowan A., Schnidrig D., Shepherd STC, Shum B., Byrne F., Goicoechea M., Piperni E. et al., 2023/06/02. Cancer discovery, 13 (6) pp. 1364-1385. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_28FC808E66FB]
COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases.
Martin P., Tsourti Z., Ribeiro J., Castelo-Branco L., de Azambuja E., Gennatas S., Rogado J., Sekacheva M., Šušnjar S., Viñal D. et al., 2023/06. ESMO open, 8 (3) p. 101566. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_94155F804FBD]
Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer.
Chen Y., Li H., Janowczyk A., Toro P., Corredor G., Whitney J., Lu C., Koyuncu C.F., Mokhtari M., Buzzy C. et al., 2023/05/17. NPJ breast cancer, 9 (1) p. 40. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_201782BCB903]
Semiautomated Pipeline to Quantify Tumor Evolution From Real-World Positron Emission Tomography/Computed Tomography Imaging.
Abler D., Courlet P., Dietz M., Gatta R., Girard P., Munafo A., Wicky A., Jreige M., Guidi M., Latifyan S. et al., 2023/05. JCO clinical cancer informatics, 7 pp. e2200126. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_D61806C1E839]
Multiomics uncover the proinflammatory role of Trpm4 deletion after myocardial infarction in mice.
Boukenna M., Rougier J.S., Aghagolzadeh P., Pradervand S., Guichard S., Hämmerli A.F., Pedrazzini T., Abriel H., 2023/04/01. American journal of physiology. Heart and circulatory physiology, 324 (4) pp. H504-H518. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_16DA65EA38D7]
QuantImage v2: a comprehensive and integrated physician-centered cloud platform for radiomics and machine learning research.
Abler D., Schaer R., Oreiller V., Verma H., Reichenbach J., Aidonopoulos O., Evéquoz F., Jreige M., Prior J.O., Depeursinge A., 2023/03/22. European radiology experimental, 7 (1) p. 16. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EBB87EC8BBD4]
 
Single Seminal Vesicle Metastasis From Dorsal Melanoma Detected by 18 F-FDG PET/CT and Confirmed by Biopsy.
Testart Dardel N., Isenborghs E., Valerio M., Michielin O., Schaefer N., 2023/03/01. Clinical nuclear medicine, 48 (3) pp. e151-e152. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E552B0535E6B]
Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma.
Krebs F.S., Moura B., Missiaglia E., Aedo-Lopez V., Michielin O., Tsantoulis P., Bisig B., Trimech M., Zoete V., Homicsko K., 2023/02/24. International journal of molecular sciences, 24 (5) p. 4520. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E3A48A3138B7]
Dendritic cells direct circadian anti-tumour immune responses.
Wang C., Barnoud C., Cenerenti M., Sun M., Caffa I., Kizil B., Bill R., Liu Y., Pick R., Garnier L. et al., 2023/02. Nature, 614 (7946) pp. 136-143. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_33489F389D05]
 
Oncologie : ce qui a changé en 2022 [Oncology: what's new in 2022]
Nguyen-Ngoc T., Abdelhamid K., Degrauwe N., Galland S., Serena A., Christofis M., Mederos N., Bouchaab H., Diciolla A., Dris N. et al., 2023/01/18. Revue medicale suisse, 19 (N° 809-10) pp. 52-57. Peer-reviewed.
[DOI][Pmid][serval:BIB_FAF585D3813B]
Interactive process mining of cancer treatment sequences with melanoma real-world data.
Wicky A., Gatta R., Latifyan S., Micheli R., Gerard C., Pradervand S., Michielin O., Cuendet M.A., 2023. Frontiers in oncology, 13 p. 1043683. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_DD5F930248D5]
Multilingual RECIST classification of radiology reports using supervised learning.
Mottin L., Goldman J.P., Jäggli C., Achermann R., Gobeill J., Knafou J., Ehrsam J., Wicky A., Gérard C.L., Schwenk T. et al., 2023. Frontiers in digital health, 5 p. 1195017. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E6AA8FD72F0E]
2022
Visual masking deficits in schizophrenia: a view into the genetics of the disease through an endophenotype.
Shaqiri A., Hodel F., da Cruz J.R., Roinishvili M., Chkonia E., Brand A., Fellay J., Herzog M.H., 2022/12/31. Translational psychiatry, 12 (1) p. 529. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_47A6F37C5EAD]
Estimated Costs of the Ipilimumab-Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma.
Gautron Moura B., Gerard C.L., Testart N., Caikovski M., Wicky A., Aedo-Lopez V., Berthod G., Homicsko K., Prior J.O., Dromain C. et al., 2022/12/21. Cancers, 15 (1) p. 31. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0AF72365A8C3]
A differential process mining analysis of COVID-19 management for cancer patients.
Cuendet M.A., Gatta R., Wicky A., Gerard C.L., Dalla-Vale M., Tavazzi E., Michielin G., Delyon J., Ferahta N., Cesbron J. et al., 2022/12/07. Frontiers in oncology, 12 p. 1043675. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_98AD494947E5]
Nucleus-wide analysis of coherent RNA pol II movement in the context of chromatin dynamics in living cancer cells.
Shaban H.A., 2022/12. Nucleus, 13 (1) pp. 313-318. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7C3A725DF54E]
Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
Röhrig U.F., Majjigapu S.R., Vogel P., Reynaud A., Pojer F., Dilek N., Reichenbach P., Ascenção K., Irving M., Coukos G. et al., 2022/12. Journal of enzyme inhibition and medicinal chemistry, 37 (1) pp. 1773-1811. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EF494F840FDA]
Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries.
Cortellini A., Dettorre G.M., Dafni U., Aguilar-Company J., Castelo-Branco L., Lambertini M., Gennatas S., Angelis V., Sita-Lumsden A., Rogado J. et al., 2022/11. Journal for immunotherapy of cancer, 10 (11) pp. e005732. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_43EB088625EB]
Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events.
Coukos A., Vionnet J., Obeid M., Bouchaab H., Peters S., Latifyan S., Wicky A., Michielin O., Chtioui H., Moradpour D. et al., 2022/10. Journal for immunotherapy of cancer, 10 (10) pp. e005635. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F836C2B098EA]
Towards a national strategy for digital pathology in Switzerland.
Janowczyk A., Baumhoer D., Dirnhofer S., Grobholz R., Kipar A., de Leval L., Merkler D., Michielin O., Moch H., Perren A. et al., 2022/10. Virchows Archiv, 481 (4) pp. 647-652. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_329EB5DFD086]
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).
Ascierto P.A., Agarwala S.S., Blank C., Caracò C., Carvajal R.D., Ernstoff M.S., Ferrone S., Fox B.A., Gajewski T.F., Garbe C. et al., 2022/09/04. Journal of translational medicine, 20 (1) p. 391. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4E798A46CDF9]
An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves.
Wysocki O., Zhou C., Rogado J., Huddar P., Shotton R., Tivey A., Albiges L., Angelakas A., Arnold D., Aung T. et al., 2022/08/16. Cancers, 14 (16) p. 3931. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AB438C1281CE]
 
Structure-based prediction of BRAF mutation classes using machine-learning approaches.
Krebs F.S., Britschgi C., Pradervand S., Achermann R., Tsantoulis P., Haefliger S., Wicki A., Michielin O., Zoete V., 2022/07/22. Scientific reports, 12 (1) p. 12528. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5CB3AA02B4B8]
Meta-omics-aided isolation of an elusive anaerobic arsenic-methylating soil bacterium.
Viacava K., Qiao J., Janowczyk A., Poudel S., Jacquemin N., Meibom K.L., Shrestha H.K., Reid M.C., Hettich R.L., Bernier-Latmani R., 2022/07. The ISME journal, 16 (7) pp. 1740-1749. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B03B7173E581]
 
Author Correction: Clinical relevance of tumour-associated macrophages.
Pittet M.J., Michielin O., Migliorini D., 2022/06..
[DOI][WoS][Pmid][serval:BIB_60BF1DA61627]
 
Clinical relevance of tumour-associated macrophages.
Pittet M.J., Michielin O., Migliorini D., 2022/06. Nature reviews. Clinical oncology, 19 (6) pp. 402-421. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B8D7D43FF169]
COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE).
Castelo-Branco L., Tsourti Z., Gennatas S., Rogado J., Sekacheva M., Viñal D., Lee R., Croitoru A., Vitorino M., Khallaf S. et al., 2022/06. ESMO open, 7 (3) p. 100499. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_880DB2367FE3]
Radiomics in Oncological PET Imaging: A Systematic Review-Part 1, Supradiaphragmatic Cancers.
Morland D., Triumbari EKA, Boldrini L., Gatta R., Pizzuto D., Annunziata S., 2022/05/27. Diagnostics, 12 (6) p. 1329. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_00EE9C0034E7]
Radiomics in Oncological PET Imaging: A Systematic Review-Part 2, Infradiaphragmatic Cancers, Blood Malignancies, Melanoma and Musculoskeletal Cancers.
Morland D., Triumbari EKA, Boldrini L., Gatta R., Pizzuto D., Annunziata S., 2022/05/27. Diagnostics, 12 (6) p. 1330. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2EED7AD51340]
 
Computational Analysis of Routine Biopsies Improves Diagnosis and Prediction of Cardiac Allograft Vasculopathy.
Peyster E.G., Janowczyk A., Swamidoss A., Kethireddy S., Feldman M.D., Margulies K.B., 2022/05/24. Circulation, 145 (21) pp. 1563-1577. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D4B7F5D8AB29]
Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma.
Homicsko K., Dummer R., Hoeller C., Wolchok J.D., Hodi F.S., Larkin J., Ascierto P.A., Atkinson V., Robert C., Postow M.A. et al., 2022/05/05. Cancers, 14 (9) p. 2300. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4D579FC357B1]
 
Telomere Length Declines in Persons With Human Immunodeficiency Virus Before Antiretroviral Therapy Start but Not After Viral Suppression: A Longitudinal Study Over >17 Years.
Schoepf I.C., Thorball C.W., Ledergerber B., Kootstra N.A., Reiss P., Raffenberg M., Engel T., Braun D.L., Hasse B., Thurnheer C. et al., 2022/05/04. The Journal of infectious diseases, 225 (9) pp. 1581-1591. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_39DB29D8297F]
Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital.
Lee R.J., Wysocki O., Zhou C., Shotton R., Tivey A., Lever L., Woodcock J., Albiges L., Angelakas A., Arnold D. et al., 2022/05. JCO clinical cancer informatics, 6 pp. e2100177. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A5BE25E8275C]
Machine Learning to Predict Risk of Relapse Using Cytologic Image Markers in Patients With Acute Myeloid Leukemia Posthematopoietic Cell Transplantation.
Arabyarmohammadi S., Leo P., Viswanathan V.S., Janowczyk A., Corredor G., Fu P., Meyerson H., Metheny L., Madabhushi A., 2022/05. JCO clinical cancer informatics, 6 pp. e2100156. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C24FD79A1874]
Identification of New Vulnerabilities in Conjunctival Melanoma Using Image-Based High Content Drug Screening.
Nardou K., Nicolas M., Kuttler F., Cisarova K., Celik E., Quinodoz M., Riggi N., Michielin O., Rivolta C., Turcatti G. et al., 2022/03/19. Cancers, 14 (6) p. 1575. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_878327B7BEC9]
Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors.
Drobni Z.D., Michielin O., Quinaglia T., Zlotoff D.A., Zubiri L., Gilman H.K., Supraja S., Merkely B., Muller V., Sullivan R.J. et al., 2022/03. European journal of cancer, 163 pp. 108-118. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_79B502336559]
Safety and Efficacy of Ipilimumab plus Nivolumab and Sequential Selective Internal Radiation Therapy in Hepatic and Extrahepatic Metastatic Uveal Melanoma.
Aedo-Lopez V., Gérard C.L., Boughdad S., Gautron Moura B., Berthod G., Digklia A., Homicsko K., Schaefer N., Duran R., Cuendet M.A. et al., 2022/02/24. Cancers, 14 (5) p. 1162. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8F8308EFA619]
Oncologie [2021 Oncology update]
Meyer M.L., Chrysou K., Stamatiou A., Gilabert M., Herrera Gomez R.G., Latifyan S., Masmoudi S., Mederos N., Perrinjaquet C., Berthold D. et al., 2022/02/02. Revue medicale suisse, 18 (767) pp. 182-186. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_BB8819FD3196]
 
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.
Goldinger S.M., Buder-Bakhaya K., Lo S.N., Forschner A., McKean M., Zimmer L., Khoo C., Dummer R., Eroglu Z., Buchbinder E.I. et al., 2022/02. European journal of cancer, 162 pp. 22-33. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FC41A790D28F]
Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning-Assisted Gland Analysis.
Xie W., Reder N.P., Koyuncu C., Leo P., Hawley S., Huang H., Mao C., Postupna N., Kang S., Serafin R. et al., 2022/01/15. Cancer research, 82 (2) pp. 334-345. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4CB64CF66EFE]
The SwissSimilarity 2021 Web Tool: Novel Chemical Libraries and Additional Methods for an Enhanced Ligand-Based Virtual Screening Experience.
Bragina M.E., Daina A., Perez MAS, Michielin O., Zoete V., 2022/01/12. International journal of molecular sciences, 23 (2) p. 811. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9174E37AD078]
SwissBioisostere 2021: updated structural, bioactivity and physicochemical data delivered by a reshaped web interface.
Alessandro C., Antoine D., Marta A S P., Olivier M., Vincent Z., 2022/01/07. Nucleic acids research, 50 (D1) pp. D1382-D1390. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B45F1019EA9E]
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies.
Michielin O., Lalani A.K., Robert C., Sharma P., Peters S., 2022/01. Journal for immunotherapy of cancer, 10 (1) pp. e003024. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8EB4E8449258]
Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma.
Federico Paly V., Kurt M., Zhang L., Butler M.O., Michielin O., Amadi A., Hernlund E., Johnson H.M., Kotapati S., Moshyk A. et al., 2022. MDM policy & practice, 7 (1) p. 23814683221089659. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_0DDC4E311C75]
Impact of scanner variability on lymph node segmentation in computational pathology.
Khan A., Janowczyk A., Müller F., Blank A., Nguyen H.G., Abbet C., Studer L., Lugli A., Dawson H., Thiran J.P. et al., 2022. Journal of pathology informatics, 13 p. 100127. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_5C4383C0E205]
MMO-Net (Multi-Magnification Organ Network): A use case for Organ Identification using Multiple Magnifications in Preclinical Pathology Studies.
Gámez Serna C., Romero-Palomo F., Arcadu F., Funk J., Schumacher V., Janowczyk A., 2022. Journal of pathology informatics, 13 p. 100126. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_C481755AE74A]
 
Structural Prediction of Peptide–MHC Binding Modes
Perez Marta A. S., Cuendet Michel A., Röhrig Ute F., Michielin Olivier, Zoete Vincent, 2022. pp. 245-282 dans Computational Peptide Science, Springer US.
[DOI][Pmid][serval:BIB_5B61FB9FCC6D]
2021
Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation.
Duraiswamy J., Turrini R., Minasyan A., Barras D., Crespo I., Grimm A.J., Casado J., Genolet R., Benedetti F., Wicky A. et al., 2021/12/13. Cancer cell, 39 (12) pp. 1623-1642.e20. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4A546D8AF05A]
 
Turning tumors from cold to inflamed to improve immunotherapy response.
Gerard C.L., Delyon J., Wicky A., Homicsko K., Cuendet M.A., Michielin O., 2021/12. Cancer treatment reviews, 101 p. 102227. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4AB33FCA1873]
Quick Annotator: an open-source digital pathology based rapid image annotation tool.
Miao R., Toth R., Zhou Y., Madabhushi A., Janowczyk A., 2021/11. The journal of pathology. Clinical research, 7 (6) pp. 542-547. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AE1D6CF05BEF]
 
Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
Hilbers M.L., Dimitriou F., Lau P., Bhave P., McArthur G.A., Zimmer L., Kudura K., Gérard C.L., Levesque M.P., Michielin O. et al., 2021/10. European journal of cancer, 156 pp. 149-163. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A82FBE1EAA00]
 
1686P Selecting patient-reported outcomes to monitor symptomatic toxicities of immune-checkpoint inhibitors: A Delphi study
Lopes A.M.D.S., Colomer-Lahiguera S., Mederos-Alfonso N-N., Lopez V. Aedo, Spurrier-Bernard G., Tolstrup L.K., Pappot H., Aspeslagh S., Rogiers A., Neyns B. et al., 2021/09., ESMO Congress 2021 pp. S1180 dans Annals of Oncology.
[DOI][WoS][serval:BIB_8EB95DA9992D]
Acute cardiac manifestations under immune checkpoint inhibitors-beware of the obvious: a case report.
Arangalage D., Pavon A.G., Özdemir B.C., Michielin O., Schwitter J., Monney P., 2021/08. European heart journal. Case reports, 5 (8) pp. ytab262. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E2AAE474DB65]
 
Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply.
da Silva I.P., Ahmed T., Reijers ILM, Warner A.B., Patrinely J.R., Serra-Bellver P., Allayous C., Mangana J., Zimmer L., Trojaniello C. et al., 2021/08. The Lancet. Oncology, 22 (8) pp. e343-e344. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D51407044D20]
Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab.
Thouvenin L., Charrier M., Clement S., Christinat Y., Tille J.C., Frigeri M., Homicsko K., Michielin O., Bodmer A., Chappuis P.O. et al., 2021/08. Gynecologic oncology reports, 37 p. 100787. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AB2F51C1A9EA]
 
Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy.
Hepner A., Atkinson V.G., Larkin J., Burrell R.A., Carlino M.S., Johnson D.B., Zimmer L., Tsai K.K., Klein O., Lo S.N. et al., 2021/08. European journal of cancer, 153 pp. 213-222. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1A7F34C37268]
 
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma.
Haas L., Elewaut A., Gerard C.L., Umkehrer C., Leiendecker L., Pedersen M., Krecioch I., Hoffmann D., Novatchkova M., Kuttke M. et al., 2021/07. Nature cancer, 2 (7) pp. 693-708. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_630A38C698EC]
 
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma.
Owen C.N., Bai X., Quah T., Lo S.N., Allayous C., Callaghan S., Martínez-Vila C., Wallace R., Bhave P., Reijers ILM et al., 2021/07. Annals of oncology, 32 (7) pp. 917-925. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4024F0C5F587]
Machine learning analyses of antibody somatic mutations predict immunoglobulin light chain toxicity.
Garofalo M., Piccoli L., Romeo M., Barzago M.M., Ravasio S., Foglierini M., Matkovic M., Sgrignani J., De Gasparo R., Prunotto M. et al., 2021/06/10. Nature communications, 12 (1) p. 3532. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8025CE5AB3D3]
 
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Pires da Silva I., Ahmed T., Reijers ILM, Weppler A.M., Betof Warner A., Patrinely J.R., Serra-Bellver P., Allayous C., Mangana J., Nguyen K. et al., 2021/06. The Lancet. Oncology, 22 (6) pp. 836-847. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_001DC1DD3B64]
Cystathionine-gamma-lyase overexpression in T cells enhances antitumor effect independently of cysteine autonomy.
Lancien M., Gueno L., Salle S., Merieau E., Beriou G., Nguyen T.H., Abidi A., Dilek N., Solomon P., Poschmann J. et al., 2021/05. Cancer science, 112 (5) pp. 1723-1734. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_145E54BFE34D]
 
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.
Ghisoni E., Wicky A., Bouchaab H., Imbimbo M., Delyon J., Gautron Moura B., Gérard C.L., Latifyan S., Özdemir B.C., Caikovski M. et al., 2021/05. European journal of cancer, 149 pp. 153-164. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4791AD7F437D]
 
Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response.
Dimitriou F., Zaremba A., Allayous C., Kähler K.C., Gerard C.L., Festino L., Schäfer S., Toussaint F., Heinzerling L., Hassel J.C. et al., 2021/05. European journal of cancer, 149 pp. 37-48. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CDCE3AC07754]
Suivi téléphonique des patients testés positifs au SARS-CoV-2 au Département d’oncologie du CHUV [Telephone follow-up of SARS-CoV-2 positive patients at the Oncology Department of Lausanne University Hospital]
Jankovic J., Da Silva Lopes A.M., Morez A., Darnac C., Demicheli R., Dalla-Vale M., Lauriers N., Garcia Sanchez J., Bouchaab H., Ninane F. et al., 2021/04/07. Revue medicale suisse, 17 (733) pp. 703-707. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_B502B1BCD7F4]
Impact de la pandémie de Covid sur la détection des cancers de la peau [Impact of COVID pandemic on the detection of skin cancer]
Triboulet C., Amblas A., Vernez M., Michielin O., Gaide O., 2021/03/31. Revue medicale suisse, 17 (732) pp. 635-639. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_729DC505DFD7]
 
Probing the Conformational Dynamics of Affinity-Enhanced T Cell Receptor Variants upon Binding the Peptide-Bound Major Histocompatibility Complex by Hydrogen/Deuterium Exchange Mass Spectrometry.
Merkle P.S., Trabjerg E., Hongjian S., Ferber M., Cuendet M.A., Jørgensen TJD, Luescher I., Irving M., Zoete V., Michielin O. et al., 2021/03/23. Biochemistry, 60 (11) pp. 859-872. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CF7649E47A67]
Swiss-PO: a new tool to analyze the impact of mutations on protein three-dimensional structures for precision oncology.
Krebs F.S., Zoete V., Trottet M., Pouchon T., Bovigny C., Michielin O., 2021/03/18. NPJ precision oncology, 5 (1) p. 19. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A929D45E3DA0]
 
Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity.
Hong A., Piva M., Liu S., Hugo W., Lomeli S.H., Zoete V., Randolph C.E., Yang Z., Wang Y., Lee J.J. et al., 2021/03. Cancer discovery, 11 (3) pp. 714-735. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_642840149803]
 
Feature-driven local cell graph (FLocK): New computational pathology-based descriptors for prognosis of lung cancer and HPV status of oropharyngeal cancers.
Lu C., Koyuncu C., Corredor G., Prasanna P., Leo P., Wang X., Janowczyk A., Bera K., Lewis J., Velcheti V. et al., 2021/02. Medical image analysis, 68 p. 101903. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F03686275BC7]
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Ressler J.M., Karasek M., Koch L., Silmbrod R., Mangana J., Latifyan S., Aedo-Lopez V., Kehrer H., Weihsengruber F., Koelblinger P. et al., 2021/02. Journal for immunotherapy of cancer, 9 (2) pp. e001701. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_044C379CA9CC]
Development and evaluation of deep learning-based segmentation of histologic structures in the kidney cortex with multiple histologic stains.
Jayapandian C.P., Chen Y., Janowczyk A.R., Palmer M.B., Cassol C.A., Sekulic M., Hodgin J.B., Zee J., Hewitt S.M., O'Toole J. et al., 2021/01. Kidney international, 99 (1) pp. 86-101. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6E8CC43CC1A4]
2020
Pharmacogénomique et aide à la prescription médicamenteuse [Pharmacogenomics : a toolbox to improve drug prescription]
Jaccard E., Redin C., Girardin F., Waeber G., Fellay J., Vollenweider P., 2020/11/25. Revue medicale suisse, 16 (716) pp. 2259-2263. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_227B3780CEBD]
Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience.
Trama A., Proto C., Whisenant J.G., Torri V., Cortellini A., Michielin O., Barlesi F., Dingemans A.C., Van Meerbeeck J., Pancaldi V. et al., 2020/11/09. Cancer cell, 38 (5) pp. 602-604. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6F92D71268C4]
Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART.
Wan C., Bachmann N., Mitov V., Blanquart F., Céspedes S.P., Turk T., Neumann K., Beerenwinkel N., Bogojeska J., Fellay J. et al., 2020/11/02. Nature communications, 11 (1) p. 5542. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EC2E5183286F]
A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study.
Lu C., Bera K., Wang X., Prasanna P., Xu J., Janowczyk A., Beig N., Yang M., Fu P., Lewis J. et al., 2020/11. The Lancet. Digital health, 2 (11) pp. e594-e606. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E48BB8C87F06]
 
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee.
Michielin O., van Akkooi A., Lorigan P., Ascierto P.A., Dummer R., Robert C., Arance A., Blank C.U., Chiarion Sileni V., Donia M. et al., 2020/11. Annals of oncology, 31 (11) pp. 1449-1461. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_80D2F0076B33]
 
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee.
Keilholz U., Ascierto P.A., Dummer R., Robert C., Lorigan P., van Akkooi A., Arance A., Blank C.U., Chiarion Sileni V., Donia M. et al., 2020/11. Annals of oncology, 31 (11) pp. 1435-1448. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B130050026C9]
Trametinib Induces the Stabilization of a Dual GNAQ p.Gly48Leu- and FGFR4 p.Cys172Gly-Mutated Uveal Melanoma. The Role of Molecular Modelling in Personalized Oncology.
Krebs F.S., Gérard C., Wicky A., Aedo-Lopez V., Missiaglia E., Bisig B., Trimech M., Michielin O., Homicsko K., Zoete V., 2020/10/28. International journal of molecular sciences, 21 (21) pp. E8021. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_44F221AEB60A]
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.
Zhang Q., Bastard P., Liu Z., Le Pen J., Moncada-Velez M., Chen J., Ogishi M., Sabli IKD, Hodeib S., Korol C. et al., 2020/10/23. Science, 370 (6515) pp. eabd4570. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_38514EC06F0A]
Evolving impact of long-term survival results on metastatic melanoma treatment.
Michielin O., Atkins M.B., Koon H.B., Dummer R., Ascierto P.A., 2020/10. Journal for immunotherapy of cancer, 8 (2) pp. e000948. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CD4A9414B04C]
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus.
Curigliano G., Banerjee S., Cervantes A., Garassino M.C., Garrido P., Girard N., Haanen J., Jordan K., Lordick F., Machiels J.P. et al., 2020/10. Annals of oncology, 31 (10) pp. 1320-1335. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_957BAED3FD8F]
Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives.
Middleton M.R., Hoeller C., Michielin O., Robert C., Caramella C., Öhrling K., Hauschild A., 2020/09. British journal of cancer, 123 (6) pp. 885-897. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_ED664BCFFB6F]
 
Clinical deployment of AI for prostate cancer diagnosis.
Janowczyk A., Leo P., Rubin M.A., 2020/08. The Lancet. Digital health, 2 (8) pp. e383-e384. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0455C9CC5657]
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.
Garassino M.C., Whisenant J.G., Huang L.C., Trama A., Torri V., Agustoni F., Baena J., Banna G., Berardi R., Bettini A.C. et al., 2020/07. The Lancet. Oncology, 21 (7) pp. 914-922. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7ACA42FE2BEB]
TERAVOLT: Thoracic Cancers International COVID-19 Collaboration.
Whisenant J.G., Trama A., Torri V., De Toma A., Viscardi G., Cortellini A., Michielin O., Barlesi F., Dingemans A.C., Van Meerbeeck J. et al., 2020/06/08. Cancer cell, 37 (6) pp. 742-745. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F9BFA1700A3B]
Cardiotoxicité des inhibiteurs de points de contrôle immunitaire utilisés dans le traitement des cancers [Cardiotoxicity of immune checkpoint inhibitors used in cancer treatment]
Arangalage D., Pavon A.G., Hugelshofer S., Desgraz B., Tzimas G., Delyon J., Muller O., Obeid M., Ribi C., Michielin O. et al., 2020/06/03. Revue medicale suisse, 16 (696) pp. 1165-1168. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_A124D4D50BD9]
Mélanome localement avancé et métastatique : nouveautés [Locally advanced and metastatic melanoma : novelties]
Huber A., Latifyan S., Nikolopoulou A., Homicsko K., Berthod G., Michielin O., Özdemir B.C., 2020/05/27. Revue medicale suisse, 16 (695) pp. 1092-1097. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_E5DDB348D97F]
 
Personalized treatment of immune checkpoint inhibitor-related severe hemophagocytic lymphohistiocytosis (HLH).
Obeid Michel, Özdemir Berna C., Latifyan Sofiya, Michielin Olivier, 2020/05/20. Journal of Clinical Oncology, 38 (15_suppl) pp. e15079-e15079. Peer-reviewed.
[DOI][serval:BIB_2C5E572A5602]
Oncologie : naviguer la pandémie de COVID-19 et garder le cap [Oncology: navigating the COVID-19 Pandemic and Steer the Course]
Zimmermann S., Dietrich P.Y., Michielin O., Betticher D., Peters S., 2020/04/29. Revue medicale suisse, 16 (N° 691-2) pp. 819-822. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_0B2FC89C06E5]
The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019.
Ascierto P.A., Agarwala S.S., Eggermont A., Gershenwald J.E., Grob J.J., Hamid O., Michielin O., Postow M., Puzanov I., Zarour H.M. et al., 2020/04/16. Journal of translational medicine, 18 (1) p. 171. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_B856D78550C3]
 
First-Line Selective Internal Radiation Therapy in Patients with Uveal Melanoma Metastatic to the Liver.
Ponti A., Denys A., Digklia A., Schaefer N., Hocquelet A., Knebel J.F., Michielin O., Dromain C., Duran R., 2020/03. Journal of nuclear medicine, 61 (3) pp. 350-356. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4FD86FE51A57]
HLA Heterozygote Advantage against HIV-1 Is Driven by Quantitative and Qualitative Differences in HLA Allele-Specific Peptide Presentation.
Arora J., Pierini F., McLaren P.J., Carrington M., Fellay J., Lenz T.L., 2020/03/01. Molecular biology and evolution, 37 (3) pp. 639-650. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4A4E20C0A676]
Integrating radiomics into holomics for personalised oncology: from algorithms to bedside.
Gatta R., Depeursinge A., Ratib O., Michielin O., Leimgruber A., 2020/02/07. European radiology experimental, 4 (1) p. 11. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_4D7640250026]
Oncologie [Advances in Oncology 2019]
Vernadou A., Ferahta N., Mederos N., Ferraro D., Dischl-Antonioni I., Diciolla A., Liapi A., Mosimann V., Latifyan S., Aedo-Lopez V. et al., 2020/01/15. Revue medicale suisse, 16 (676-7) pp. 72-77. Peer-reviewed.
[URN][Pmid][serval:BIB_7B31C4DA5F5B]
Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss.
Frisone D., Charrier M., Clement S., Christinat Y., Thouvenin L., Homicsko K., Michielin O., Bodmer A., Chappuis P.O., McKee T.A. et al., 2020. Cancer biology & therapy, 21 (3) pp. 197-202. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_DDF548EFECDC]
 
The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
Martins F., Schiappacasse L., Levivier M., Tuleasca C., Cuendet M.A., Aedo-Lopez V., Gautron Moura B., Homicsko K., Bettini A., Berthod G. et al., 2020/01. Journal of neuro-oncology, 146 (1) pp. 181-193. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_18BD1C202E95]
2019
Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient.
Pillonel V., Dunet V., Hottinger A.F., Berthod G., Schiappacasse L., Peters S., Michielin O., Aedo-Lopez V., 2019/12/02. Journal for immunotherapy of cancer, 7 (1) p. 336. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9C48A9CE403D]
 
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.
Michielin O., van Akkooi ACJ, Ascierto P.A., Dummer R., Keilholz U., ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org, 2019/12/01. Annals of oncology, 30 (12) pp. 1884-1901. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A63CBCEEA279]
 
Deep Response to Anti-PD-1 Therapy of Metastatic Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumor With CD274/PD-L1 Amplification.
Özdemir B.C., Bohanes P., Bisig B., Missiaglia E., Tsantoulis P., Coukos G., Montemurro M., Homicsko K., Michielin O., 2019/12. JCO precision oncology, 3 pp. 1-6. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E12437A0DD54]
 
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.
Dafni U., Michielin O., Lluesma S.M., Tsourti Z., Polydoropoulou V., Karlis D., Besser M.J., Haanen J., Svane I.M., Ohashi P.S. et al., 2019/12/01. Annals of oncology, 30 (12) pp. 1902-1913. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DF9E566FB280]
Herpes simplex encephalitis in adult patients with MASP-2 deficiency.
Bibert S., Piret J., Quinodoz M., Collinet E., Zoete V., Michielin O., Menasria R., Meylan P., Bihl T., Erard V. et al., 2019/12. PLoS pathogens, 15 (12) pp. e1008168. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_568322E0BDD0]
 
The Romand Network of Oncology: bridging the gap of personalised oncology
Michielin O., Tsantoulis P., Homicsko K., Christinat Y., De Leval L., Bisig B., Missiaglia E., Zoete V., Krebs F., Fortin A. et al., 2019/10/18. Swiss Medical Weekly.
[serval:BIB_2A3947B3BCE2]
 
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Martins F., Sofiya L., Sykiotis G.P., Lamine F., Maillard M., Fraga M., Shabafrouz K., Ribi C., Cairoli A., Guex-Crosier Y. et al., 2019/09. Nature reviews. Clinical oncology, 16 (9) pp. 563-580. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7F8DDEE8DA1E]
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy).
Ascierto P.A., Agarwala S.S., Botti G., Budillon A., Davies M.A., Dummer R., Ernstoff M., Ferrone S., Formenti S., Gajewski T.F. et al., 2019/07/22. Journal of translational medicine, 17 (1) p. 234. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_76EC1D50A2F5]
 
MedCo: Enabling Secure and Privacy-Preserving Exploration of Distributed Clinical and Genomic Data
Raisaro Jean Louis, Troncoso-Pastoriza Juan Ramon, Misbach Mickael, Sousa Joao Sa, Pradervand Sylvain, Missiaglia Edoardo, Michielin Olivier, Ford Bryan, Hubaux Jean-Pierre, 2019/07/01. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 16 (4) pp. 1328-1341. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EB26A9E809D5]
 
La médecine personnalisée en oncologie dans: Médecine Personnalisée
Colomer-Lahiguera S., Coukos G., Peters S., Kandalaft L., Michielin O., Eicher M., 2019. dans Médecine Personnalisée, Académie Suisse de Sciences Médicales.
[serval:BIB_B2FAEFC8A271]
2018
CD73 expression and clinical significance in human metastatic melanoma.
Monteiro I., Vigano S., Faouzi M., Treilleux I., Michielin O., Ménétrier-Caux C., Caux C., Romero P., de Leval L., 2018/06/01. Oncotarget, 9 (42) pp. 26659-26669. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_11E2460193C6]
 
Practice-Changing Developments in Stage III Melanoma: Surgery, Adjuvant Targeted Therapy, and Immunotherapy.
Kudchadkar R.R., Michielin O., van Akkooi ACJ, 2018/05/23. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 38 pp. 759-762. Peer-reviewed.
[DOI][Pmid][serval:BIB_F4007C299F82]
 
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
Tanyi Janos L., Bobisse Sara, Ophir Eran, Tuyaerts Sandra, Roberti Annalisa, Genolet Raphael, Baumgartner Petra, Stevenson Brian J., Iseli Christian, Dangaj Denarda et al., 2018/04/11. Science Translational Medicine, 10 (436) pp. eaao5931.
[DOI][WoS][Pmid][serval:BIB_641968BB356B]
 
Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma.
Tétu P., Mangana J., Dummer R., Dutriaux C., Beneton N., Dalle S., Meyer N., Oriano B., Michielin O., Lebbe C., 2018/04. European journal of cancer, 93 pp. 147-149. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4C2D9AD34505]
Comment on "MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma".
Voruz S., Martins F., Cairoli A., Naveiras O., Homicsko K., Missiaglia E., de Leval L., Bisig B., Michielin O., Blum S., 2018/03. Haematologica, 103 (3) pp. e130. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0845E1BF99E5]
ECCO essential requirements for quality cancer care: Melanoma.
Wouters M.W., Michielin O., Bastiaannet E., Beishon M., Catalano O., Del Marmol V., Delgado-Bolton R., Dendale R., Trill M.D., Ferrari A. et al., 2018/02. Critical reviews in oncology/hematology, 122 pp. 164-178. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_51AB46916AFB]
Lymphatic vessel density is associated with CD8<sup>+</sup> T cell infiltration and immunosuppressive factors in human melanoma.
Bordry N., Broggi MAS, de Jonge K., Schaeuble K., Gannon P.O., Foukas P.G., Danenberg E., Romano E., Baumgaertner P., Fankhauser M. et al., 2018. Oncoimmunology, 7 (8) pp. e1462878. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AD8EABFF0764]
Phase I, open-label study of pasireotide in patients with <i>BRAF-</i>wild type and <i>NRAS</i>-wild type, unresectable and/or metastatic melanoma.
Dummer R., Michielin O., Nägeli M.C., M Goldinger S., Campigotto F., Kriemler-Krahn U., Schmid H., Pedroncelli A., Micaletto S., Schadendorf D., 2018. ESMO open, 3 (5) pp. e000388. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_373D1B523FF6]
2017
 
Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma.
Fankhauser M., Broggi MAS, Potin L., Bordry N., Jeanbart L., Lund A.W., Da Costa E., Hauert S., Rincon-Restrepo M., Tremblay C. et al., 2017/09/13. Science translational medicine, 9 (407) pp. 1-13. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C55698C8F509]
2016
 
Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope
Baumgaertner P., Costa Nunes C., Cachot A., Maby-El Hajjami H., Cagnon L., Braun M., Derré L., Rivals J.-P., Rimoldi D., Gnjatic S. et al., 2016/10/02. OncoImmunology, 5 (10) pp. e1216290.
[DOI][WoS][Pmid][serval:BIB_B9A2EC467477]
Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8(+) and CD4(+) T-cell responses with multiple specificities including a novel DR7-restricted epitope.
Baumgaertner P., Costa Nunes C., Cachot A., Maby-El Hajjami H., Cagnon L., Braun M., Derré L., Rivals J.P., Rimoldi D., Gnjatic S. et al., 2016. Oncoimmunology, 5 (10) pp. e1216290. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_A6A68301DF3E]
2015
 
Immuno-Oncology
Michielin Olivier, Coukos George, 2015/09/09. Progress in Tumor Research, 42, S. Karger AG.
[DOI][serval:BIB_3BABB0481053]
STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
Demaria O., De Gassart A., Coso S., Gestermann N., Di Domizio J., Flatz L., Gaide O., Michielin O., Hwu P., Petrova T.V. et al., 2015. Proceedings of the National Academy of Sciences of the United States of America, 112 (50) pp. 15408-15413.
[URN][DOI][WoS][Pmid][serval:BIB_572BDFE9D6A6]
2014
 
Successes and Limitations of Targeted Cancer Therapy in Melanoma
Peters Solange, Stahel RA (eds.)Romano Emanuela, Michielin Olivier, 2014. Progress in Tumor Research, 41, S. KARGER AG.
[DOI][WoS][Pmid][serval:BIB_CBD38C70CA73]
2011
 
Structure-function analyses point to a polynucleotide-accommodating groove essential for APOBEC3A restriction activities.
Bulliard Y., Narvaiza I., Bertero A., Peddi S., Röhrig U.F., Ortiz M., Zoete V., Castro-Díaz N., Turelli P., Telenti A. et al., 2011. Journal of Virology, 85 (4) pp. 1765-1776.
[DOI][WoS][Pmid][serval:BIB_512FB2191F5A]
2008
 
Molecular Dynamics-based Free Energy Simulations
Cuendet M. A., Zoete V., Michielin O., 2008/05., WORLD SCIENTIFIC.
[DOI][serval:BIB_AAAC9CB47F2A]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University